This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Quest Diagnostics (DGX) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Quest Diagnostics (DGX) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Quest Diagnostics (DGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks For July 16th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Medtronic Banks on Ventilator Sales Amid Coronavirus Crisis
by Zacks Equity Research
Medtronic (MDT) is currently focusing on the geographical diversification of its businesses, apart from product innovation. Also, it demonstrates a strong solvency position.
Masimo (MASI) Introduces Automation and Connectivity Solution
by Zacks Equity Research
Masimo's (MASI) UniView: 60 leverages the Masimo Hospital Automation platform to boost clinical workflows.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Integra Reports Organic Sales Drop in Preliminary Q2 Results
by Zacks Equity Research
Integra (IART) projects a severe impact on revenues due to the coronavirus-led economic crisis despite sequential improvement in monthly sales performance throughout the quarter.
Here's Why You Should Retain Merit Medical (MMSI) for Now
by Zacks Equity Research
Investor confidence is high on Merit Medical (MMSI) stock, thanks to solid prospects.
DGX vs. USPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DGX vs. USPH: Which Stock Is the Better Value Option?
Here's Why You Should Retain Integer Holdings Stock for Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from solid presence in the broader MedTech space and portfolio management.
Allscripts Extends Strategic Partnership With Microsoft
by Zacks Equity Research
Allscripts (MDRX) extends partnership with Microsoft that can help transform healthcare with smarter technology, thereby improving patient outcomes.
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Luminex (LMNX) continues to benefit from robust product portfolio, solid molecular diagnostics and ARIES platforms.
BD Collaborates With BARDA to Combat Coronavirus Crisis
by Zacks Equity Research
Becton, Dickinson (BDX) forms a strategic public-private partnership with BARDA to help the U.S. government in its efforts to fight the COVID-19 pandemic and future pandemics.
Henry Schein Banks on Dental Consumable Amid Coronavirus Woes
by Zacks Equity Research
Henry Schein (HSIC) seems upbeat about its dental technology business, Henry Schein One.
Henry Schein Medical to Expand in Telemedicine With VisualDx
by Zacks Equity Research
Henry Schein's (HSIC) VisualDx system to be integrated with Medpod's technology infrastructure for improved patient outcome.
QIAGEN (QGEN) Reports Encouraging Preliminary Q2 Results
by Zacks Equity Research
Preliminary net revenues for second-quarter 2020 improved 18-19% at CER.
Baxter Gets FDA Nod for Altapore Shape Bioactive Bone Graft
by Zacks Equity Research
Baxter (BAX) receives FDA approval for Altapore Shape that will provide surgeons versatile options to advance the art of healing and boost clinical outcomes during a surgery.
Hologic Expands Product Portfolio With New Ultrasound System
by Zacks Equity Research
Hologic's (HOLX) latest cart-based ultrasound system enhances efficiency and accuracy to better meet the requirements of breast imagers and optimize patient care.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Investor confidence is high on Nevro (NVRO), thanks to solid prospects
Medtronic's LINQ II ICM Gets Multiple Regulatory Approvals
by Zacks Equity Research
Medtronic's (MDT) FDA and CE Mark-approved LINQ II ICM enables physicians to optimize device settings via remote programming, without requiring patients' in-office visits.
Bio-Rad (BIO) Banks on Coronavirus PCR Tests Amid Cost Woes
by Zacks Equity Research
Bio-Rad (BIO) rides on the FDA's emergency use authorization EUA for the Droplet Digital PCR COVID-19 test kit.
Zacks.com featured highlights include: Sprouts Farmers Market, Patterson Companies, Sleep Number, T-Mobile US and Quest Diagnostics
by Zacks Equity Research
Zacks.com featured highlights include: Sprouts Farmers Market, Patterson Companies, Sleep Number, T-Mobile US and Quest Diagnostics
Medtronic Launches User-Friendly Insulin Infusion Set in US
by Zacks Equity Research
Medtronic's (MDT) MiniMed Mio Advance infusion set, is aimed at providing optimal user experience to insulin pump-using diabetic patients.
LabCorp Launches At-Home Coronavirus Test Collection Kit
by Zacks Equity Research
LabCorp (LH) claims this to be the first digital COVID-19 service that physicians can use to remotely diagnose patients before any surgery or procedure.